Switching and emergence of CTL epitopes in HIV-1 infection

Chungyong Han1,10, Ai Kawana-Tachikawa1, Akihisa Shimizu1, Dayong Zhu1, Hitomi Nakamura2,3, Eisuke Adachi3, Tadashi Kikuchi1,3, Michiko Koga1, Tomohiko Koibuchi3, George F Gao4, Yusuke Sato5,6, Atsushi Yamagata5,6, Eric Martin7,8, Shuya Fukai5,6, Zabrina L Brumme7,8 and Aikichi Iwamoto1,2,3,9*

Abstract

Background: Human Leukocyte Antigen (HLA) class I restricted Cytotoxic T Lymphocytes (CTLs) exert substantial evolutionary pressure on HIV-1, as evidenced by the reproducible selection of HLA-restricted immune escape mutations in the viral genome. An escape mutation from tyrosine to phenylalanine at the 135th amino acid (Y135F) of the HIV-1 nef gene is frequently observed in patients with HLA-A*24:02, an HLA Class I allele expressed in ~70% of Japanese persons. The selection of CTL escape mutations could theoretically result in the \textit{de novo} creation of novel epitopes, however, the extent to which such dynamic “CTL epitope switching” occurs in HIV-1 remains incompletely known.

Results: Two overlapping epitopes in HIV-1 nef, Nef126-10 and Nef134-10, elicit the most frequent CTL responses restricted by HLA-A*2402. Thirty-five of 46 (76%) HLA-A*24:02-positive patients harbored the Y135F mutation in their plasma HIV-1 RNA. Nef codon 135 plays a crucial role in both epitopes, as it represents the C-terminal anchor for Nef126-10 and the N-terminal anchor for Nef134-10. While the majority of patients with 135F exhibited CTL responses to Nef126-10, none harboring the “wild-type” (global HIV-1 subtype B consensus) Y135 did so, suggesting that Nef126-10 is not efficiently presented in persons harboring Y135. Consistent with this, peptide binding and limiting dilution experiments confirmed F, but not Y, as a suitable C-terminal anchor for HLA-A*2402. Moreover, experiments utilizing antigen specific CTL clones to recognize endogenously-expressed peptides with or without Y135F indicated that this mutation disrupted the antigen expression of Nef134-10. Critically, the selection of Y135F also launched the expression of Nef126-10, indicating that the latter epitope is created as a result of escape within the former.

Conclusions: Our data represent the first example of the \textit{de novo} creation of a novel overlapping CTL epitope as a direct result of HLA-driven immune escape in a neighboring epitope. The robust targeting of Nef126-10 following transmission (or \textit{in vivo} selection) of HIV-1 containing Y135F may explain in part the previously reported stable plasma viral loads over time in the Japanese population, despite the high prevalence of both HLA-A*24:02 and Nef-Y135F in circulating HIV-1 sequences.

Background

Cytotoxic T lymphocytes (CTLs) are key players in the immune control of Human Immunodeficiency Virus 1 (HIV-1), as they recognize virally-derived peptide epitopes presented by HLA class I molecules on the infected cell surface \cite{1,2}. Over the course of infection however, HIV-1 mutations arise within the infected individual, notably in targeted CTL epitopes, that allow the virus to escape immune recognition by CTLs. Importantly, despite the hypermutability of HIV-1, these immune escape mutations often arise in a stereotypical manner \cite{3,4} that is highly predictable based on the specific HLA class I molecules expressed by the host \cite{5,6,7,8}. Although selection of HLA-associated mutations in HIV-1 is driven by immune pressure, these amino acid substitutions sometimes result in the induction of a \textit{de novo} immune response in which the mutant epitope is recognized by a TCR associated with a different CTL subset \cite{7,9}. What is less well-characterized is the
extent to which selection of immune escape mutations result in the de novo creation of novel CTL epitopes nearby, that could subsequently be targeted by CTL in vivo (in a manner similar to the continual exposure of novel antibody epitopes in HIV-1 envelope as a consequence of escape from earlier humoral responses [10]). Here, we demonstrate such a dynamic phenomenon of “CTL epitope switching” as a direct result of CTL escape from HLA-A*24:02.

We reported previously that the substitution from tyrosine to phenylalanine (Y135F) at the 135th amino acid of the HIV-1 nef gene is frequently observed in patients with HLA-A*24:02, an HLA Class I allele expressed in ~70% of Japanese persons [4,11]. Our observation that Y135F appeared to be an escape mutation was later confirmed [12]. In order to examine the influence of HIV-1 mutations on the strength of various epitope-specific CTL responses, we studied CTL epitopes restricted by HLA-A*24:02 in relatively conserved regions of the HIV-1 genome. Our results indicate that Nef135F, selected to escape recognition of a well-described HLA-A*24:02-restricted CTL epitope in this viral protein, results in the creation of another HLA-A*24:02 epitope immediately upstream. To our knowledge, our findings represent the first evidence of immune escape-driven “epitope switching” in HIV-1 infection.

Results
Identification of immunodominant CTL responses restricted by HLA-A*24:02
Forty-six HLA-A*24:02-positive patients with HIV-1 infection were studied. Forty-four were infected through unprotected sexual intercourse and 2 were hemophiliacs. Forty-five were infected with subtype B except one was infected with subtype AG. The median plasma viral load (pVL) was 4.11 (range 2.26 to 5.36) log 10 copies/ml, and the median CD4 cell count was 395 (range 120 to 1,035) cells/μl. To determine which published HLA-A*24:02-restricted CTL epitope are most frequently recognized among persons expressing this allele, IFN-γ ELISpot assays were performed using expanded PBMCs. Due to limited PBMC numbers, 11 published A*24:02-restricted CTL epitopes in the relatively conserved gag, pol and nef regions [13-15] were selected for investigation. Published optimal epitopes were used for the assay. The response rate against Nef134-10 was highest (80.4%), followed by Nef126-10 (50.0%), Gag28-9 (40.0%) and Pol496-9 (28.3%), while limited (<10%) or no responses were observed in the other epitopes (Figure 1A, B). Of note, Nef126-10 and Nef134-10 overlap each other by 2 amino acids (Figure 1A).

We next analyzed patient plasma HIV RNA amino acid sequences within the Nef126-10–Nef134-10 regions (Table 1). The great majority of patients (35/46 = 76.1%) had a tyrosine (Y) to phenylalanine (F) mutation (Y135F) at Nef codon 135 (Nef135F) while eight patients (8/46 = 17.4%) had the global consensus subtype B residue at this position (Nef135Y). Two were Nef135L and one was Nef135W. These results were consistent with our earlier findings [4]. Intriguingly, none of the eight patients with Nef135Y exhibited a Nef126-10-specific response, while all of them exhibited a Nef134-10-specific response (p < 0.001, Fisher’s exact test) (Figure 1C, left). Of the 35 patients harboring Nef135F, 23 (65.7%) and 28 (80.0%) responded to Nef126-10 and Nef134-10, respectively (Figure 1C, right) (p = 0.2823, Fisher’s exact test).

Dramatic improvement in the HLA-binding affinity of Nef126-10 following mutation of the C-terminal anchor residue
To clarify the relationship between Y135F and peptide-specific responses, we examined HLA-binding affinity of the wild type and mutant peptides using in vitro peptide-HLA binding assays (Figure 2A). In context of the Nef134-10 epitope, the mutant Y135F peptide (representing position 1, the N-terminal anchor of this epitope; Nef134-10(2F)) was almost as effective as the “wild type” Nef134-10 (Nef134-10(wt)) peptide in binding to HLA-A*24:02. In contrast, in context of the Nef126-10 epitope, the mutant Y135F peptide (representing position 10, the C-terminal anchor of this epitope), dramatically improved its binding to HLA-A*24:02. The presence of threonine (T) at the 8th position (Nef126-10(8T10F)), representing Nef mutation I133T, did not significantly affect epitope-HLA binding compared to the wild type isoleucine (I) (Nef126-10(8I10F)). These results are compatible with previous reports identifying Y or F as possible N-terminal anchors for HLA-A*24:02, but only F as a possible C-terminal anchor [16,17].

We then examined the effect of the mutations on epitope recognition using CTL clones established from patients with HIV-1 infection. 293FT-A24DRm-CY0 cells pulsed with different dilutions of peptides were co-cultured with CTL cell clones. The Nef134-10-specific CTL clone H27-9 produced IFN-γ almost equally well in response to Nef134-10(2F) peptides or to Nef134-10(2F) peptides (Figure 2B, left). In contrast, the Nef126-10-specific CTL clone I30-1 produced IFN-γ only at high concentrations of the wild-type Nef126-10(2F) peptide, whereas mutant peptides Nef126-10(8I10F) and Nef126-10(8T10F) induced strong responses at very low peptide concentration (Figure 2B, right). These results were consistent with peptide-HLA binding assays suggesting that the I133T mutation did not have much effect on recognition of the epitope-HLA complex by the Nef126-10-specific CTL clone I30-1. Moreover, the results were consistent with the observation that the presence of
wild-type Y at the C-terminus lowers the affinity of the Nef126-10 peptide to HLA-A*24:02 (Figure 2A).

**CTL responses against the endogenously expressed epitopes**

In order to examine whether intracellularly-derived Nef protein could still be targeted by peptide-specific CTLs, we constructed nef-minigene expression vectors, pmNef (wt)-hRluc-EGFP, pmNef(135F)-hRluc-EGFP, and pmNef (133T135F)-hRluc-EGFP, for the generation of polypeptides encompassing the Nef126-10 and Nef134-10 epitopes (Figure 3A). The vectors encoded EGFP as a transfection marker, as well as the Renilla Luciferase (Rluc) gene hooked to the mini-nef gene by a GlyGlyGly-GlySer linker. Rluc activity served as a quantitative reference for the expression of the mini-nef polypeptide. Each vector was transfected into 293FT-A24DRm-CY0 cells. Rluc activities indicated that three types of nef-minigenes were expressed well and to comparable levels (Figure 3B).

We and others reported previously that Y135F is a processing mutation, as CTL responses could be induced to mutant epitopes via peptide-pulsing, but not via intracellularly-expressed polypeptide [4,12,18]. Consistent with the previous results, Nef134-10-specific responses by CTL clone H27-9 were induced by the wild type minigene, but diminished to minimal levels by the presence of Y135F or I133T/Y135F (Figure 3C, left). By contrast, Nef126-10-specific responses by CTL clone I30-1 were provoked dramatically by the presence of Nef135F. Specifically, the Nef126-10-specific CTL clone I30-1 showed much higher responses to antigen-presenting cells transfected with the 133I/135F or 133T/135F minigene than Nef134-10-specific CTL clone H27-9. The I30-1 responses to minigenes encoding I versus T at the Nef133 position did not substantially differ (Figure 3C, right). In contrast, I30-1 responses to the wild type
minigene were indistinguishable from background. These results suggest that wild-type Nef126-10 peptide was not expressed as an epitope on the surface of the antigen-presenting cells when expressed endogenously, but Nef126-10 containing 135F (regardless of variation at position 133) was efficiently expressed. In turn, these in vitro results (Figure 2 and 3) strongly suggest that a novel mechanism, i.e. “epitope switching” was taking place after the selection of the Y135F mutation in vivo (Figure 1). Namely, selection of Y135F facilitates escape from CTL responses targeting the first epitope (Nef134-10), but simultaneously results in the creation of another epitope upstream (Nef126-10).

**“Epitope switching” during the clinical course of HIV-1 infection**

Among 8/46 patients in the IMSUT cohort who initially harbored the “wild type” (global consensus B) Y135 residue within the Nef134-10 epitope, we identified one patient who subsequently selected 135F, followed by 133T, over a period of 12 months. We performed IFN-γ ELISpot assays on PBMCs expanded from corresponding frozen longitudinal samples (Figure 4A). Before the mutated viruses became the majority, specific responses to Nef134-10(wt) were the most prominent, followed by responses to Nef134-10(2F) (Figure 4B, left). Importantly, no Nef126-10-specific responses were observed at these time points. After plasma viruses were replaced by viruses with 133T/135F, robust responses against Nef126-10(8I10F) and Nef126-10(8T10F) were observed, while responses against Nef126-10(wt) were detected only at high peptide concentrations (Figure 4B, right). These results were consistent with the results in vitro using CTL clones (Figure 2B, right), and support the in vivo presentation of Nef126-10 only after selection of Y135F. Of interest, responses against Nef134-10 peptides decreased but remained detectable after the selection of 135F and 133T/135F mutations.

**Coupled selection of Nef135F and Nef133T mutants in vivo**

We investigated the correlation between Nef135F and Nef133T in silico in two other independent cohorts. In a large cohort of antiretroviral-naïve patients chronically infected with subtype B HIV-1 in British Columbia, Canada (British Columbia HOMER cohort), positive correlations between Nef135F and Nef133T (Odds ratio: 11.3), as well as between Nef135Y and Nef133I (Odds ratio: 16.3) were observed (Figure 5A, all p < 0.0001). Furthermore, in a multicenter longitudinal acute/early infection cohort comprising 16 HLA-A*24:02-expressing persons infected with subtype B HIV-1, selection of Nef135F preceded that of Nef133T by a short duration (Figure 5B). The median times to Y135F and I133T selection were 220 and 236 days, respectively, a difference that was not statistically significant.

The correlation between the magnitude of Nef126-10 (8I10F) or Nef126-10(8T10F)-specific response and pVL was assessed in 24 IMSUT cohort participants for whom Nef126-10(8I10F) and Nef126-10(8T10F) responses (measured by IFN-γ ELISpot) and pVL at the corresponding time point, were available (Figure 5C). Interestingly, Nef126-10(8I10F)-specific but not Nef126-10(8T10F)-specific responses were inversely correlated with pVL, suggesting that responses to the former, but not the latter, contribute to in vivo immune control.

**Crystal structures of Nef126-10 epitopes presented on HLA-A*24:02**

In order to examine the impact of these mutations on epitope structure, we solved the crystal structures of HLA-A24/Nef126-10(8I10F) and HLA-A24/Nef126-10
(8T10F) at 1.66 Å and 2.0 Å resolution, respectively (Figure 6A top and bottom; Additional file 1: Figure S1A, B). Superposition of the Nef126-10(8I10F) and Nef126-10(8T10F) peptide structures showed almost similar backbone atoms, with root mean square deviation of 0.307 Å, but conformational differences were found at P6 (131P) and P9 (134R) residues. The side chains of P6 and P9 residues in the Nef126-10(8I10F) and Nef126-10(8T10F) epitopes had poor electron densities in spite of structures being at modestly higher resolution (Additional file 1: Figure S1C, D). In addition, the B-factors for the central portions (P5-P7) of each peptide (41.5 Å² for the Nef126-10(8I10F) and 46.2 Å² for Nef126-10(8T10F)) were higher than for overall peptides (24.1 Å² for Nef126-10(8I10F) and 33.2 Å² for Nef126-10(8T10F)). These results indicated a flexibility of the central portion and P9 residue in both peptides, accounting for the structural difference observed.

The side chains of P8-Ile and P8-Thr protruded from, rather than being buried within, the antigen-binding cleft of HLA-A*24:02, suggesting the P8 residue could be involved in the contact with TCR (Figure 6A bottom). Therefore, different TCRs could be favored by the presence of either hydrophobic P8-I or hydrophilic P8-T at the interface of a TCR-HLA-A*24:02/Nef126-10. If this is the case, different TCR repertoires would be selected by Nef126-10(8I10F) or Nef126-10(8T10F), suggesting Nef-I133T as a possible immune escape mutation that alters the in vivo repertoire of CTL recognizing this epitope.

**Immune responses against Nef126-10 epitopes**

We compared the epitope-specific immune responses between two groups of individuals: those whose plasma viruses were 133I/135F (n = 4) or 133T/135F (n = 10). *Ex vivo* IFN-γ ELISpot assays using PBMCs and Nef126-10(8I10F) or Nef126-10(8T10F) revealed that 0 of 4 patients with Nef126-10(8I10F) viruses had Nef126-10 (8T10F)-specific responses (Figure 6B). Nine out of 10 patients with Nef126-10(8T10F) viruses exhibited specific
responses to the circulating epitope, and 7 of 10 patients retained the response specific against Nef126-10(8I10F). These results strongly suggested that the I133T mutation induced a new subset of CD8+ T cells capable of recognizing Nef126-10(8T10F) \( (p = 0.005, \text{Fisher's exact test}) \).

Functional avidity has been reported as a correlate of CTL selective pressure \[19,20\]. As such, we analyzed functional avidities of Nef126-10-specific CTLs. Nine individuals harboring 133T/135F were analyzed by limiting dilution (Figure 6C). Nef126-10(8I10F)-specific CTL responses showed significantly higher avidities compared to those against Nef126-10(8T10F) \( (p = 0.005, \text{Fisher's exact test}) \). The hypothesis that Nef-I133T is an A*24-driven escape mutation is additionally supported by numerous HLA-association studies in HIV subtype B-infected populations including Japan, which consistently demonstrate highly significant associations between A*24 and Nef-I133T \[4,8,21,22\].

**Discussion**

HLA-A*24:02 is highly prevalent among East Asians including Japanese \[11\]. In an effort to identify immunodominant CTL epitopes presented by HLA-A*24:02, we observed that the two most frequently-recognized epitopes lay in Nef and overlapped each other by two amino acids. Nef codon 135 is critical to both epitopes, as it represents the N-terminal anchor for the downstream epitope Nef134-10, and the C-terminal anchor

![Figure 3](http://www.retrovirology.com/content/11/1/38/figure3)

**Figure 3** Recognition of endogenously derived epitope. (A) Vector construction. The vector expresses EGFP as a transfection marker and a fusion protein that consists of mini-Nef gene coding 31 amino acids of Nef123-Nef153 region and GlyGlyGlySer linker and renilla luciferase. The 133I/135F and 133T/135F mutant vectors as well as wild type vector were constructed. Mini-Nef sequence that corresponds to the actual Nef gene is shown. (B) By measuring luciferase activity, quantity of the generated mini-Nef was assessed. No significant differences in mini-Nef generation between wild type, 135F and 133T/135F were observed. Each stick and bar indicates average and standard deviation of three independent experiments. (C) The vector transfected cells were incubated with either H27-9 or I30-1, and IFN-γ secretion was quantified by ELISA and normalized to determine the epitope recognition. For normalization, each value was divided by IFN-γ secretion with wild type peptide concentration of 9 μM. Mock as well as mGag, transfected with mGag(wt)-hRluc-EGFP, were measured as negative controls. Each stick and bar indicates average and standard deviation of three independent experiments. The significance was calculated by unpaired Student's t-test; **, \( p < 0.01 \); ***, \( p < 0.001 \).
for the upstream epitope Nef126-10. In the downstream epitope Nef134-10, the Y-to-F mutation (Y135F) at the second position is observed at high frequencies in circulating HIV-1 sequences in Japan – in fact it represents the consensus at this position in Japan - presumably as a result of high HLA-A*24:02 prevalence in the population [4,23]. Our experiments using a Nef134-10-specific CTL clone and a minigene corroborated the earlier observation that the Y135F mutation disrupts antigen processing of the Nef134-10 epitope (Figure 3C) [4,12]. Importantly, while the majority of patients with Y135F responded to the upstream epitope Nef126-10, none of the patients with the wild-type sequence responded to this epitope. Consistent with this observation, results of the peptide binding (Figure 2A) and limiting dilution experiments using antigen-specific CTLs (Figure 2B) were compatible with the previous reports indicating that F, but not Y, could serve as a C-terminal anchor [16,17]. Also consistent with this observation is that the 2nd position of Nef126-10 is Y, a strong N-terminal anchor amino acid for HLA-A*24:02. Taken together, in a process similar to the ongoing exposure of novel antibody epitopes in HIV-1 envelope as a consequence of escape from earlier humoral responses [10], our results demonstrate that an analogous phenomenon also occurs with CTL responses: in this case a novel A*24:02-restricted “epitope switch” from Nef134-10 to Nef126-10, as a result of immune-driven escape at a single Nef codon.

We also showed that Nef residues I133T and Y135F are highly significantly linked in vivo. Nef126-10 emerges as a CTL epitope by the introduction of the Y135F mutation. Though I133T has previously been identified as an HLA-A*24:02-associated polymorphism in statistical association studies [4,8,21,22,24,25], its mechanism remained unknown. Our data strongly suggest that I133T is HLA-A*24:02-restricted escape mutation whose mechanism of action is alteration of the in vivo CTL repertoire capable of recognizing the HLA-bound epitope. Although the sample size was limited, patients with 133I/135F viruses did not exhibit responses to Nef126-10(8T10F) (Figure 6B). These results, together with studies of a patient whose plasma viral sequences shifted from wild-type to 133T/135F, strongly suggest that immune pressures selected an I-to-T substitution at Nef’s 133rd position. IFN-γ ELISpot assays showed that Nef126-10(8I10F)-specific but not Nef126-10(8T10F)-specific responses
correlated inversely with pVL (Figure 5C) and that the former had significantly higher functional avidities (Figure 6C). These findings therefore suggest a TCR-mediated mechanism underlying HLA-A*24:02-mediated escape via I133T. Although higher functional avidity is a hallmark of CTLs with stronger selective pressure [19,20], further studies are needed to confirm that the I133T mutation alleviates immune pressures directed on the Nef126-10 epitope.

Crystal structures of peptide-HLA showed that the side chain of the 133rd residue (P8 residue in the Nef126-10 epitope) protruded from the peptide-binding cleft presumably providing a feature of the Nef126-10 epitope to the TCRs (Figure 6A). The shorter side chain of T compared to I might make the Nef126-10(8T10F) less accessible to TCR than the Nef126-10(8I10F) epitope. Considering the similarity of the structures, the absence of the T cell repertoire against the Nef126-10(8T10F) epitope in the patients with 133I/135F viruses is an enigma. The suggested structural flexibility of the central portion (P5-P7) and P9 of the Nef126-10 epitope may be relevant here.

A key remaining question is why the Y135F mutation is repeatedly selected by A*24:02, given that a consequence of this escape is the introduction of another A*24:02 epitope immediately upstream. We offer the following hypothesis. In studies of HIV-1 infected populations around the globe, the association between HLA-A*24:02 and Nef-135F consistently ranks among the strongest in the HIV proteome [8,21], including in Japan where F (rather than the global subtype B consensus Y) represents the consensus at this position [4,22]. Indeed, a recent international cohort study revealed an odds ratio of >28 and a p-value of 8x10^{-118} for this association [21]. The extraordinary magnitude of this association indicates that Nef-135 is under similarly extraordinary selection pressure by A*24 in vivo - presumably due to highly effective CTL responses against the Nef134–10 epitope. The benefits to HIV of evading A*24-mediated recognition of Nef134–10 presumably outweigh its substantial negative consequences to the virus, which in this case include the creation of the adjacent Nef126-10 epitope. That Nef126-10 is targeted by less than 70% of A*24-expressing
persons harboring 135F is consistent with escape at this position affording clear viral advantage in at least some cases.

We therefore propose the following model of HLA-A*24:02-mediated CTL targeting of these overlapping Nef epitopes in vivo. If an HLA-A*24:02-expressing patient were to be infected with the wild type virus, CTL responses would first arise against Nef134-10, eliciting the Y135F escape mutant. This in turn would reveal the novel Nef126-10 epitope, against which CTL responses would then arise. Similarly, if an HLA-A*24:02 expressing patient were to be infected with a virus harboring Y135F (a likely occurrence given its extremely high prevalence in Japan), we infer that a CTL response against Nef126-10 epitope would be launched immediately following infection.

As such HIV’s evasion of Nef134-10-specific CTL (either via transmission or in vivo selection of Y135F) yields a major, albeit temporary advantage to HIV, that is subsequently diminished by the creation of the Nef126-10 epitope that is then targeted in most A*24:02-expressing persons. By extension, the “epitope switching” from Nef134-10 to Nef126-10 may contribute in part to the previous observation of relatively stable pVL over time among HLA-A*24:02 positive patients [26] despite high transmission frequency of 135F [4]. These observations are not inconsistent with the idea that population-level HIV adaptation to HLA could lead to weakening of host antiviral control if “HLA-adapted” forms dominated the population (as is the case with Nef-135F in Japan, which represents the consensus at this position) [27]. If the consensus at Nef codon 135 was the susceptible Y rather than the escaped F in Japan, we hypothesize that control of HIV by A*24 would be even greater in this region, as Nef134–10 and Nef126–10 would be sequentially targeted (rather than just Nef126–10 in the case where 135F is acquired at transmission).

Of note, among the 46 patients in the IMSUT cohort, there were no significant differences in plasma HIV load between patients with or without Nef126-10-specific
characterized an example of escape-induced proteins involved. Although in the present study we are often critical to the structure and function of the viral city, and other biochemical properties suggest that they acid residue pairs with respect to size, charge, hydrophobicity, and other biochemical properties suggest that they are often critical to the structure and function of the viral proteins involved. Although in the present study we characterized an example of escape-induced “epitope switching” in HIV-1, we do not know how often this phenomenon occurs. If an HLA-driven escape mutation has the potential to serve as an anchor of a cryptic epitope, and if an N-terminal or C-terminal anchor residue is present at a proper distance, incorporation of both the wild-type and the mutant peptide in a vaccine may elicit immune response to that cryptic epitope. The vaccine-induced CTL repertoire may be useful following selection of the escape mutant or may prevent its selection altogether. As such, the phenomenon of escape-induced “epitope switch” may be relevant to vaccine design.

Conclusions
Our data represent the first example of the de novo creation of a novel overlapping CTL epitope as a direct result of HLA-driven immune escape in a neighboring epitope. The robust targeting of Nef126-10 following transmission (or in vivo selection) of HIV-1 containing Y135F may explain in part the previously reported stable plasma viral loads over time in the Japanese population, despite the high prevalence of both HLA-A*24:02 and Nef-Y135F in circulating HIV-1 sequences.

Methods
Patients and samples
The samples and host/viral genotype data analyzed in this study were obtained from three independent sources: (i) the IMSUT cohort at the Institute of Medical Science, the University of Tokyo, Japan, (ii) the baseline (pre-therapy) cross-section of the HOMER cohort in British Columbia, Canada ([8] and unpublished), and (iii) a longitudinal multicenter cohort of acute/early infected individuals [28]. The IMSUT cohort, which consists primarily of Asian patients with chronic infection, was used to determine the viral sequences and immune responses.

IMSUT cohort
Forty-six HLA-A*24:02-positive, antiretroviral-naïve, chronically HIV-infected subjects were selected from among patients participating in an ongoing HIV-1 immunopathogenesis study at an HIV outpatient clinic affiliated with the Institute of Medical Science, the University of Tokyo (IMSUT). Study procedures included routine collection of blood samples for virologic and immunologic testing. Peripheral blood mononuclear cells (PBMCs) and plasma samples were separated and preserved in liquid nitrogen or at −80°C, respectively, until use. The study was approved by the internal review board of the Institute of the Medical Science of the University of Tokyo (No. 11–2), and all subjects were adults and provided written informed consent.

HOMER cohort
A total of 1038 patients from the HAART Observational Medical Evaluation and Research (HOMER) cohort, an open cohort of initially antiretroviral-naïve chronically HIV-infected individuals in British Columbia, Canada of predominantly Caucasian ethnicity, were analyzed in the present study. Plasma HIV-1 RNA sequencing and HLA class I sequence-based typing were performed as previously described [8]. We applied phylogenetically-corrected methods [25] to determine the strength of association between amino acid variants at Nef codons 133 and 135 in this dataset.

Longitudinal acute/early infection cohort
Kaplan-Meier analysis was used to investigate the time course of selection of specific immune escape mutations at Nef codons 133 and 135 among 16 HLA-A*24 expressing individuals from a longitudinal, multicenter, acute/early HIV-1 infection cohort [28]. “Time to escape” was defined as the number of days elapsed between estimated infection date and first detection of the escape variant (as a full or partial amino acid change).

Plasma viral RNA sequences
Viral RNA was extracted from 140 μl of plasma using the QIAamp viral RNA Mini kit (QIAGEN). Using 4 μl of RNA as starting material, reverse transcription and first PCR were carried out according to the manufacturer’s protocol with SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity (Invitrogen). Two μl of the first PCR product was subjected to nested PCR, performed using Ex-Taq HS (Takara) with 35 cycles of 30s at 94°C, 30s at 55°C, 60s at 72°C and a final extension for 7 min at 72°C. The primer sets were as follows (Nucleotide positions are those of the published HIV-1 SF2 strain [GenBank accession number: K02007]). For the first PCR, primers Nef-1F (5’-GTAGCTGAGGGGACAGATAGGGTTAT-3’ (nt 8,6
Expression vectors

To construct the HLA-A*24:02 expression vector, pcDNA3.1-A24-DsRedm, the HLA-A*24:02 sequence was amplified by PCR using cloned HLA-A*24:02 cDNA as a template [29,30] and digested with BamHI and Ncol. Primers (5'-TAATAGACTCAGATATAGG-3') and (5'-CCATGGATCCTCGACTCTGACGAGAGACAC-3') were used for the amplification. The pDsRed-Monomer (Invitrogen) sequence was digested by Ncol and NotI, and was ligated to the 3' end of HLA-A*24:02 fragment to obtain the HLA-A24-DsRedm fragment. Then HLA-A24-DsRedm fragment was inserted into the multiple cloning site of pcDNA3.1/Hygro (+) vector (Invitrogen).

Mini-Nef and mini-Gag gene expression vectors containing two reporter genes, renilla luciferase (RLuc) and EGFP, together with hygromycin selection were constructed in a pTracer-CMV2 vector (Invitrogen) as follows. Wild-type and mutant mini-Nef genes (from amino acid position 18 to 46 in p17) were amplified by PCR using cloned HIV-1 SF-2 Nef gene with wild-type or mutant sequence as a template [4,31,32]. Primer products were purified with a PCR purification kit (QIAGEN) before sequencing. DNA sequencing was performed using an ABI Prism dye terminator cycle sequencing-ready reaction kit (Applied Biosystems) on a Perkin-Elmer ABI-377 sequencer.

IFN-γ ELISPOT assay

The gamma interferon enzyme-linked immunospot (IFN-γ ELISPOT) assay was performed using patients’ PBMCs as previously described [4] with some modifications. In brief, 96-well plates (Millipore) were coated with anti-gamma-interferon (IFN-γ) MAb 1-D1k (Mabtech) overnight at 4°C. Peptides were added directly to the wells at a final concentration of 10^-5 M. 5 x 10^6 cells were added to each well with a final volume of 100 µl of R10. For negative controls, PBMCs were incubated with R10 alone without peptides. After incubation at 37°C under 5% CO2 overnight (16 to 18 h), the plates were washed six times with phosphate-buffered saline containing 0.01% tween-20 (PBST). Biotinylated anti-IFN-γ MAb 7-B6-1 (Mabtech) was added, and was incubated for 2 hours at 37°C under 5% CO2. After washing with PBST, IFN-γ-producing cells were detected as dark spots after 10- to 20-min color reaction with 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium by using AP Conjugate Substrate Kit (Bio-Rad). Spots were counted by KS ELISPOT compact (Carl Zeiss) and expressed as spot-forming units (SFU) per 10^6 PBMCs respectively. In the final step the GFPz sequence was replaced by EGFP sequence (Clontech).

Peptides

Synthetic peptides were purchased from Sigma-Genosys. The peptides used in the screening of immune response by ELISPOT had a purity of 70% or more. All other peptides were more than 95% pure as determined by high-performance liquid chromatography and mass spectroscopy.

Cells and media

T2-A24, a kind gift from K. Kuzushima, was cultured in RPMI 1640 (Sigma) supplemented with 100 µl of penicillin/ml, 100 U of streptomycin/ml, 10% heat-inactivated fetal calf serum (FCS) (Sigma), and 0.8 mg of G418 (Invitrogen)/ml [33]. We established Nef126-10 and Nef134-10-specific CTL clones, I30-1 and H27-9, as previously described [18]. CTL clones were cultured with RPMI 1640 supplemented with 50 U of interleukin-2/ml, 100 U of penicillin/ml, 100 U of streptomycin/ml, and 10% heat-inactivated FCS (R10/50), but the clones were cultured in the absence of interleukin-2 (R10) for two days before antigen presentation assays. pcDNA3.1-A24-DsRedm was introduced into 293FT cell line (Invitrogen) and the cells were treated by hygromycin for 2 weeks. After cloning by limiting dilution we obtained 293FT-A24DRm-CY0, and confirmed HLA-A*24:02 expression with FACS analysis by using anti-HLA-A9 serotype antibody (One Lambda, data not shown).
after subtracting the SFU of the negative control. Values with >50 SFU, >3 x mean SFU of negative control and > mean SFU of negative control + 3 SD per 10⁶ input cells were considered as a positive response. Since more cells were required for the immune response screening (Figure 1B) and functional avidity assays (Figures 4B and 6C), PBMCs were stimulated with anti-human CD3 antibody and the T cells were expanded for 2 to 3 weeks in R10/50 (BD Pharmingen). Culture media was changed to R10 two days prior to the assay date. For ex vivo IFN-γ ELISpot assay (Figures 5B and 6B), PBMCs were cultured for 6 hours in R10 media.

**Peptide-HLA binding assay (Figure 2A)**
Peptide binding to HLA-A*24:02 was assessed by using a T2-A24 stabilization assay as previously described [4,33]. Briefly, after incubation for 16 hours at 26°C under 5% CO₂, 2 x 10⁵ T2-A24 cells were incubated with 10⁻⁴ to 10⁻⁹ M peptides for 1 h at 4°C. After keeping at 37°C under 5% CO₂ for 3 hours, the cells were stained with biotinylated anti-human HLA-A9 monoclonal antibody (One Lambda), and streptavidin-APC conjugates (BD Pharmingen). The mean fluorescence intensity (MFI) was measured by FACSCalibur (Becton Dickinson). In each experiment, MFI of samples was normalized by the MFI of 10⁻⁴ M control peptide, Nef134-8(RYPLTFGW).

Three independent experiments were performed.

**CTL clones and Epitope recognition (Figure 2B)**
Nef134-10- and Nef126-10-specific clones, H27-9 and I30-1, were established by Nef134-10(wt) and Nef126-10 (wt) peptide stimulation respectively, and limiting dilution of PBMCs from HIV-1-infected patients harboring 133 T/135 F. For in-vitro peptide stimulation, 5 x 10⁵ PBMCs were pulsed with 10 μM of each peptide for 1 h. The cells were washed twice with R10, then cultured with 1 x 10⁶ autologous PBMCs and 4 x 10⁶ irradiated (3300 rad) allogeneic PBMCs in R10. After 4 days, IL-2 was added to 50 U/ml and the cells were cultured for 2–3 weeks in R10/50. Peptide-specific CD8+ T cells were enriched by MACS separation (Miltenyi) using tetramers. The sorted cells were cloned by limiting dilution to 3 or 10 cells/well in 96-well round-bottom tissue culture plates, and cultured with 10⁵ irradiated allogeneic PBMCs in R10/50 containing 5 μg/ml PHA-L.

CTL-recognition of the epitopes was assessed by serially diluted peptides. On day 0, 293FT-A24DRm-CY0 cells were seeded onto 96-well flat-bottom transparent plate (BD Falcon) so that the cultures become confluent on day 2. On day 2, each peptide was pulsed with concentrations from 3² to 3⁻⁶ M to the wells and incubated at 37°C under 5% CO₂ for 1 h. Then CTLs (5,000 ~ 10,000 cells) were added and co-cultured at 37°C under 5% CO₂ for 18 to 24 h. After the incubation, supernatants were harvested, and IFN-γ concentrations were quantified by Human IFN-γ ELISA Set (BD Bioscience). In each experiment, the IFN-γ value of samples was normalized to that of the highest wild type peptide concentration (9 μM). For example, each IFN-γ value of I30-1 CTL clone was divided by the value of the well pulsed with 9 μM Nef126-10(wt) peptide. Each assay was performed in duplicate and three independent experiments were conducted.

**Antigen presentation assay (Figure 3)**
Antigen presentation was assessed by measuring epitope-specific CTL responses to endogenously expressed antigen. First, intracellular expression of each antigen was extrapolated from the activity of reporter protein, Rluc. 293FT-A24DRm-CY0 cells were seeded in 96-well plate (Nunc) on day 0. On day 1, antigen expression plasmids, pmNef(wt)-hRluc-EGFP, pmNef(135F)-hRluc-EGFP, pmNef(133T135F)-hRluc-EGFP, or control vectors (pmGag(wt)-hRluc-EGFP) were transfected into the cells in each well using FuGENE HD (Promega). The cultures were incubated at 37°C under 5% CO₂ for 18 to 24 h. On day 2, transfection efficiency was inspected roughly under a fluorescence microscope (KEYENCE BZ-9000), then Rluc activity in each transfected well was measured using Dual-Glo Luciferase Assay System (Promega) and luminometer (Promega GloMax 96 Microplate Luminometer). The assay was performed in triplicate.

Second, CTL responses against endogenously expressed and processed epitopes were evaluated. 293FT-A24DRm-CY0 cells were seeded onto a 96-well flat-bottom transparent plate (BD Falcon) on day 0. On day 1, expression plasmid was transfected to each well using FuGENE HD (Promega). CTLs (5,000 ~ 10,000 cells) were added to the transfected wells on day 2. After incubation for 18 to 24 h, the supernatant of each well was harvested, and IFN-γ secretion was quantified by Human IFN-γ ELISA Set (BD Bioscience). IFN-γ ELISA was performed in duplicate.

Experiments were performed in duplicate on three independent occasions. To normalize the values in each experiment, mean IFN-γ values of each sample were normalized by the mean value of reference wells in duplicate. In the reference wells, 9 μM of the wild type peptide was pulsed to the antigen presenting cells and then co-cultured with CTLs.

**Protein expression in E. coli, refolding and purification**
HLA-A*24:02 and β2m were expressed in E. coli and refolded from inclusion bodies as previously described with some modifications [34]. HLA-A*24:02 (18 mg), β2m (6 mg) and peptide (4 mg) were mixed in 400 ml of refold buffer containing 100 mM Tris, pH 8.0, 400 mM L-arginine-HCl, 2 mM EDTA, 5 mM GSH, 0.5 mM GSSG, 0.2 mM PMSF. The refolded protein was purified by Superdex 75 column, followed by Mono Q column, and
subsequently concentrated to 10 mg/ml in 20 mM Tris, pH 8.0, 50 mM NaCl for crystallization.

**Crystallization, data collection and structure determination**

The crystallization was done by the sitting drop vapor diffusion method at 20°C. Crystals of the A24/N126-10 (8T10F) complex were obtained in 20% (w/v) PEG 3350, 200 mM sodium phosphate dibasic, and those of A24/N126-10(8I10F) were obtained in 20% (w/v) PEG 3350, 200 mM sodium nitrate. For cryoprotection, crystals were soaked briefly in reservoir solutions containing 20% ethylene glycol, and then frozen in liquid nitrogen before data collection. Data were collected at the beamline BL41XU in SPring 8 (Hyogo, Japan), and processed with HKL2000 [35] and the CCP4 program suite [36].

The structure were determined by molecular replacement using Molrep [37]. The search model was the coordinate file of PDB (Protein Data Bank) code 3I6L with omitted peptide for A24/N126-10(8T10F). Model building and refinement were carried out using Coot [38] and REFMAC5.6 implemented in CCP4, respectively. The structure of A24/N126-10(8I10F) was determined with the refined A24/N126-10(8T10F) as a search model and refined as described above. The stereochemistry of the refined models was assessed with RAMPAGE [39]. All molecular graphic representations were created with the program PyMOL (DeLano Scientific; http://www.pymol.org). Data collection and refinement statistics are shown in Additional file 2: Table S1.

**Functional avidity assay**

Basically, the assay was performed using the same procedure with IFN-γ ELISpot assay as described above. PBMCs were cultured for 2 to 3 weeks in R10/50 after anti-human CD3 antibody (BD Pharmingen) stimulation, and culture media were changed from R10/50 to R10 two days before use. PBMCs were incubated with peptides at concentrations from 10−5 to 10−12 M, and SFU was calculated. The functional avidity to peptide dilutions was determined as a 50% of sigmoidal dose (SD50) SFU.

**Statistical analysis**

All data visualization and statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, CA). Student’s t-test and Mann–Whitney U-test were used to compare the antigen presentation and functional avidity between two groups, respectively. Spearman rank correlation was used to calculate the correlation between peptide-specific response and pVL. Dose at 50% response in sigmoidal dose–response curves (SD50) was calculated by drawing sigmoidal dose–response curves. Time to mutational escape, defined as the time elapsed between estimated date of HIV-1 infection and the first appearance of a full or partial amino acid change consistent with the specific escape mutation of interest, was calculated using Kaplan-Meier (survival) methods.

**Additional files**

### Additional file 1: Figure S1.
Overview of structures of the HLA-A*2402 in complex with the Nef126-10 peptides. Structures of (A) the A24/N126-10 (8I10F) and (B) the A24/N126-10(8T10F). The electron density of (C) the Nef126-10(8I10F) and (D) the Nef126-10(8T10F) are shown with Fo-Fc omit maps contoured at 2.0 σ. (cyan mesh). The peptide structures are shown in a side view (top panels) and top view (bottom panels). The Nef126-10 (8I10F) and the Nef126-10 (8T10F) are shown as a purple and a green stick model, respectively. HLA-A24 and β2m are represented as gray and black cartoon model, respectively.

### Additional file 2: Table S1.
Data collection and refinement statistics.
Author details
1Division of Infectious Diseases, Advanced Clinical Research Center, the Institute of Medical Science, the University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. 2Department of Infectious Disease Control, the International Research Center for Infectious Diseases, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan. 3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. 4Structural Biology Laboratory, Life Science Division, Synchrotron Radiation Research Organization and Institute of Molecular and Cellular Biosciences, the University of Tokyo, Tokyo, Tokyo, Japan. 5Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan. 6Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. 7British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada. 8Asian Research Center for Infectious Diseases, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan. 9Cancer Immunology Branch, Division of Cancer Biology, National Cancer Center, Goyang-si, Gyeonggi-do 410-769, Korea.

References
1. Michael AJ, Rowland-Jones SL: Cellular immune responses to HIV. Nature 2001, 410(6821):980–987.
2. Walker BD, Burton DR: Toward an AIDS vaccine. Science 2008, 320(5877):760–764.
3. Kawana A, Tomyama H, Takiguchi M, Shioda T, Nakamura T, Iwamoto A: Accumulation of specific amino acid substitutions in HIV-1 B35-restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte epitopes. AIDS Res Hum Retrovir 1999, 15(15):1099–1107.
4. Fukatsu T, Hosoya N, Kawana-Tachikawa A, Tomizawa M, Odawara T, Mito K, Kitamura Y, Nakamura T, Kelleher AO, Cooper DA, Iwamoto A: Frequent transmission of cytotoxic T lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HIV-A24-positive Japanese population. J Virol 2004, 78(16):8437–8445.
5. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Hopkins CE, Heckerman D, Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber M, Rizzoli M, Berger CT, Herrera MJ, Palou E, Plana M, Rolland M, Khati A, Heckerman D, Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber BK, Pavalkis GN, Mullins JL, Brander C: CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 2012, 7(1):e29717.
6. Carlson JM, Listgarten J, Brecknock MA, Le AQ, Chiu CK, Cotton LA, Knappp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Dezelj CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL, International HIV Adaptation Collaborative: Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 2012, 86(4):2302–2316.
7. Chikata T, Carlson JM, Tamura Y, Borgen MA, Naruto T, Hashimoto M, Murakoshi H, Le AQ, Mallal S, John M, Ganaeana H, Oka S, Brumme ZL, Tachiguchi M: Host-specific adaptation of HIV-1 subtype B in the Japanese population. J Virol 2014, 88(9):4764–4775.
8. Shimizu A, Kawana-Tachikawa A, Yamagata A, Han C, Zhu D, Sato Y, Nakamura H, Kobuchii T, Carlson J, Martin E, Brumme CJ, Shi Y, Gao GF, Brumme ZL, Fukai S, Iwamoto A: Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Sci Rep 2013, 3:2927.
9. Brumme ZL, John M, Carlson JM, Brecknock CJ, Chan D, Brecknock MA, Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadle CM, Fr��nh N, Brander C, Walker BD, Harrigan PR: Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007, 3(7):e74.
10. Haas G, Pikart U, Debre P, Lucaci M, Catlama C, Douduit Y, Bonduelle O, Bauer M, Elbenfeldt HG, Jung G, Maier B, Meyehans A, Autran B: Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Virol 1996, 70(15):4212–4221.
11. Wilbourn CK, Bhiman JN, Gray ES, Tumbia N, Abdool Karim SS, Williamson C, Morris L, Moore PL: Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathog 2013, 9(10):e1003578.
12. Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, Kikkawa E, Kulisik JK, Satake M, Inoko H: High-throughput DNA typing of HIV-A, −B, −C, and −DRB1 loci by a PCR-SSOP-Lumienix method in the Japanese population. Immunogenetics 2005, 57(10):717–729.
13. Fujinami R, Tanuma J, Kozumi H, Kawashima Y, Honda K, Masuoka-Alzawa S, Doi S, Oka S, Tachikawa A: Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts. J Virol 2008, 82(1):135–147.
14. Ikeda-Moore Y, Tomyama H, Miwa K, Oka S, Iwamoto A, Kanko Y, Tachikawa A: Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol 1997, 158(12):6224–6252.
15. Goulder PJ, Edwards A, Phillips RE, McMichael AJ: Identification of a novel HLA-A24-restricted cytotoxic T lymphocyte epitope within HIV-1 Nef. AIDS (London, England) 1997, 11(15):1883–1884.
16. Choppin J, Cohen W, Bianco A, Briad JP, Conann F, Dalois M, Guillet JG: Characteristics of HIV-1 nef regions containing multiple CD8+ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J Immunol 2001, 166(6):6164–6169.
17. Itoh Y, Miwa K, Kano Y, Yokota S, Tachikawa A: Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A*2402 molecules. Immunogenetics 1996, 44(4):233–241.
18. Sidney J, Southwood S, Sette A: Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires. Immunogenetics 2005, 57(6):393–408.
19. Miyazaki E, Kawana-Tachikawa A, Tomizawa M, Nunoya J, Odawara T, Fujii T, Shi Y, Gao GF, Iwamoto A: Highly restricted T cell receptor repertoire in the CD8+ T cell response against an HIV-1 epitope with a stereotyped amino acid substitution. AIDS (London, England) 2009, 23(6):651–660.
20. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, Larsen M, Pancino G, Douek DC, Autran B, Saiz-Corion A, Appay V: Antigen sensitivity is a major determinant of CD8+ T cell polyfunctionality and HIV-suppressive activity. Blood 2009, 113(25):6351–6360.
21. Mothe B, Lano A, Iamamoto J, Zamarreno J, Schiaulini M, Miranda C, Ruiz-Riolo M, Berger CT, Herrera MJ, Palou E, Plana M, Rolland M, Khati A, Heckerman D, Pereyra F, Walker BD, Weiner D, Paredes R, Cloet B, Felber BK, Pavalkis GN, Mullins JL, Brander C: CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 2012, 7(1):e29717.
22. Carlson JM, Listgarten J, Brecknock MA, Le AQ, Chiu CK, Cotton LA, Knappp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Dezelj CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL, International HIV Adaptation Collaborative: Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 2012, 86(4):2302–2316.
Walker BD: Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol 2008, 82(18):9216–9227.

29. Tokunaga K, Ishikawa Y, Ogawa A, Wang H, Mitsunaga S, Moriyama S, Lin L, Banmai M, Watanabe Y, Kashiwase K, Tanaka H, Akaza T, Tadokoro K, Yuri T: Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997, 46(3):199–205.

30. Kawana-Tachikawa A, Tomizawa M, Nunoya J, Shioda T, Kato A, Nakayama EE, Nakamura T, Nagai Y, Iwamoto A: An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes. J Virol 2002, 76(23):11982–11988.

31. York-Higgins D, Cheng-Mayer C, Bauer D, Levy JA, Dina D: Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol 1990, 64(8):4016–4020.

32. Shioda T, Levy JA, Cheng-Mayer C: Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gene gp120. Nature 1991, 349(6305):167–169.

33. Kuzushima K, Hayashi N, Kimura H, Tsunumi T: Efficient identification of HLA-A2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001, 98(6):1872–1881.

34. Cole DK, Rizkallah PJ, Gao F, Watson NI, Boulter JM, Bell JI, Sami M, Gao GF, Jakobsen BK: Crystal structure of HLA-A2402 complexed with a telomerase peptide. Eur J Immunol 2006, 36(1):170–179.

35. Otwinowski Z, Minor W: Processing of X-Ray Diffraction Data Collected in Oscillation Mode Macromolecular Crystallography. Methods Enzymol 1997, 276:307–326.

36. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, BKE, Leslie AGW, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS: Overview of the CCP4 suite and current developments. Acta Crystallogr Sect D Biol Crystallogr 2011, 67:235–242.

37. Vagin A, Teplyakov A: MOLREP: an Automated Program for Molecular Replacement. J Appl Cryst 1997, 30:1022–1025.

38. Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60(Pt 12 Pt 1):2126–2132.

39. Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC: Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins Struct Funct Genet 2003, 50(3):437–450.

doi:10.1186/1742-4690-11-38
Cite this article as: Han et al.: Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology 2014 11:38.